Health & Fitness
Health and Fitness
Health and Fitness
Thu, April 5, 2012Wed, April 4, 2012Tue, April 3, 2012Mon, April 2, 2012Sun, April 1, 2012Sat, March 31, 2012Fri, March 30, 2012Thu, March 29, 2012Wed, March 28, 2012Tue, March 27, 2012Mon, March 26, 2012Sun, March 25, 2012Sat, March 24, 2012Fri, March 23, 2012Thu, March 22, 2012Cempra, Inc. to Present at the Needham 11th Annual Health Care Conference
Published in Health and Fitness on Thursday, March 29th 2012 at 4:08 GMT by Market Wire
Cempra, Inc. to Present at the Needham 11th Annual Health Care... -- CHAPEL HILL, N.C., March 29, 2012 /PRNewswire/ --
Cempra, Inc. to Present at the Needham 11th Annual Health Care Conference
CHAPEL HILL, N.C., March 29, 2012 /PRNewswire/ -- Cempra, Inc. (Nasdaq: [ CEMP ]) today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer, will present at the Needham 11th Annual Health Care Conference at 10:40 a.m. EDT, Apr.4, 2012, at the Palace Hotel in New York. Dr. Fernandes will provide an overview of the company's two leading antibiotic clinical programs, solithromycin (CEM-101) for community-acquired bacterial pneumonia and TAKSTA™ for the chronic, oral treatment of gram positive pathogens includingmethicillin-resistant S. aureus (MRSA) in prosthetic joint infections.
The presentation will be webcast live under the events section of Cempra's website at [ www.cempra.com ] and will be archived there following the presentation for 90 days. Please connect to Cempra's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Cempra, Inc.
Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates have both completed oral Phase 2 clinical trials and seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to utilize its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about Cempra can be found at [ www.cempra.com ].
Investor Contacts:
Robert E. Flamm, Ph.D.
Russo Partners, LLC
(212) 845-4226
[ Robert.flamm@russopartnersllc.com ]
Andreas Marathovouniotis
Russo Partners, LLC
(212) 845-4235
[ Andreas.marathis@russopartnersllc.com ]
Media Contact:
Elliot Fox
Russo Partners, LLC
(212) 845-4253
[ Elliot.fox@russopartnersllc.com ]
SOURCE Cempra, Inc.
[ Back to top ] RELATED LINKS
[ http://www.cempra.com ]
